Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, Royalty Pharma plc reported revenue of $2.38B, up 5.1% year over year. Operating margin was 65.6% and net margin 32.4%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from RPRX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $2.38B | 65.6% | 32.4% |
| FY2024 | $2.26B | 57.1% | 37.9% |
| FY2023 | $2.35B | 63.4% | 48.2% |
| FY2022 | $2.24B | 13.7% | 1.9% |
| FY2021 | $2.29B | 62.5% | 27.1% |
How does RPRX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.